0.06
+0.003(+5.51%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
August 13, 2012
| Name | Title | Pay | Year Born |
| Dr. William V. Williams FCPA, M.D. | Chief Executive Officer, President & Director | 734,419 | 1955 |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 241,138 | 1946 |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer | 357,745 | 1970 |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary | 443,000 | 1973 |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer | 540,329 | 1962 |
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.